“With regards to IP and patents, Silence will vigorously enforce its patent estate where third parties are considered to be infringing the company's patent rights," said Silence chief executive, Dr David Horn Solomon
A drug that is the focus of legal action by Silence Therapeutics PLC () has been granted limited approval here in the UK.
Patisiran, a new-breed of RNAi medicine developed by American biotech Inc (), will join the Early Access to Medicines Scheme.
This means Britons with a rare neuro-degenerative disease can receive the treatment before it gains EU marketing authorisation.
Patisiran is at the centre of a court case, set for trial in December, with Silence Therapeutics claiming it infringes intellectual property (IP) the UK life sciences group developed and owns.
“With regards to IP and patents, Silence will vigorously enforce its patent estate where third parties are considered to be infringing the company's patent rights," said chief executive, Dr David Horn Solomon.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE